updated chart, page-3148

Growth stocks, including Biotech, getting bid in the US on speculation int rate tightening almost done. In fact, deflation now a concern. 2023 2024 will be a better year for Biotech. I have been adding. I also think with depressed prices, we will see big pharma embark on an M&A spree to grab all the little gems for rock bottom sale prices.

ARK Genomics has bottomed out and the 50 MA has turned above the 200 MA for the first time since June 2021. So here we are 2 years later after a bloodbath, with perhaps light at the end of the tunnel.